Ken Griffin Aravive, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$0.11 - $1.76 $1,441 - $23,056
13,100 New
13,100 $1,000
Q1 2023

May 15, 2023
SELL
$1.29 - $2.46 $16,254 - $30,996
-12,600 Reduced 65.28%
6,700 $13,000
Q4 2022

Feb 14, 2023
BUY
$1.2 - $1.83 $23,160 - $35,319
19,300 New
19,300 $25,000

Others Institutions Holding ARAV

# of Institutions
2
Shares Held
28.1K
Call Options Held
0
Put Options Held
0
View Full List

About Aravive, Inc.

ARAV Quotes by TradingView
  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email